Similar articles

• Susceptibility of aerobic gram-negative bacilli to aminoglycosides. Effects of 45 months of amikacin as first-line aminoglycoside therapy.

  Saavedra S, Vera D, Ramírez-Ronda CH. Saavedra S, et al. Am J Med. 1986 Jun 30;80(6B):65-70. doi: 10.1016/0002-9343(86)90481-x. Am J Med. 1986. PMID: 3014877
• Effectiveness of carbenicillin - aminoglycoside and of cephalothin-aminoglycoside combinations against enterococci in vitro.

  Klastersky J, Daneau D. Klastersky J, et al. Pathol Biol (Paris). 1975 May;23(5):345-8. Pathol Biol (Paris). 1975. PMID: 1105331
• Prudent use of the aminoglycosides.

  Gregory D, Hirschmann JV. Gregory D, et al. Postgrad Med. 1978 Sep;64(3):97-102, 104. doi: 10.1080/00325481.1978.11714923. Postgrad Med. 1978. PMID: 704499
• Aminoglycosides, imipenem, and aztreonam.

  Johnson JG, Hardin TC. Johnson JG, et al. Clin Podiatr Med Surg. 1992 Apr;9(2):443-64. Clin Podiatr Med Surg. 1992. PMID: 1586911 Review.
• Antimicrobial agents--Part II. The aminoglycosides: streptomycin, kanamycin, gentamicin, tobramycin, amikacin, neomycin.

  Brewer NS. Brewer NS. Mayo Clin Proc. 1977 Nov;52(11):675-9. Mayo Clin Proc. 1977. PMID: 336988 Review.